Literature DB >> 2881426

Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.

S H Bigner, H S Friedman, J A Biegel, C J Wikstrand, J Mark, R Gebhardt, L F Eng, D D Bigner.   

Abstract

The four permanent human glioma-derived cell lines reported here are the first such lines for which the karyotypes have been followed from the original biopsies through the establishment of the lines in culture. Although ploidy changes were seen, each line retained either distinctive marker chromosomes or the overall original chromosomal distribution allowing the origin of each line to be established with certainty. D-263 MG expresses glial fibrillary acidic protein, all lines except D-245 MG are tumorigenic in athymic mice, and each line displays a unique pattern with respect to in vitro growth parameters and expression of biochemically defined markers, oncofetal antigens and lymphoid-associated markers. D-245 MG and D-259 MG are able to grow in the absence of supplemental glutamine; glutamine synthetase was detected in these cell lines both by immunocytochemistry and by direct assay. Thus, the four permanent human glioma-derived cell lines described here are representative of glioma lines in their general characteristics. D-259 MG retains numerous double minute chromosomes (DMs), D-263 MG contains two marker chromosomes with breaks in 9p, and D-247 MG and D-245 MG with stemlines containing 96 and 89 chromosomes contain eight and six normal copies (respectively) of chromosome No. 7. The retention in these four cell lines of the most common chromosomal abnormalities seen in biopsies of malignant human gliomas provides the opportunity to investigate the meaning of these specific chromosomal changes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2881426     DOI: 10.1007/bf00687952

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

1.  Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.

Authors:  C J Wikstrand; D D Bigner
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

2.  Patterns of the early, gross chromosomal changes in malignant human gliomas.

Authors:  S H Bigner; J Mark; M S Mahaley; D D Bigner
Journal:  Hereditas       Date:  1984       Impact factor: 3.271

3.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma.

Authors:  J Trent; P Meltzer; M Rosenblum; G Harsh; K Kinzler; R Mashal; A Feinberg; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

6.  Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Authors:  G Dranoff; G B Elion; H S Friedman; G L Campbell; D D Bigner
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

7.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

8.  Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.

Authors:  H S Friedman; S C Schold; M Varia; D D Bigner
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

9.  Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.

Authors:  J Kurtzberg; M S Hershfield
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

10.  Chromosomal localization of human leukocyte, fibroblast, and immune interferon genes by means of in situ hybridization.

Authors:  J M Trent; S Olson; R M Lawn
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more
  8 in total

1.  DNA in human glioblastomas. A flow-fluorescence cytometrical examination of 96 tumors.

Authors:  F W Spaar; U Spaar
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

2.  Immunohistochemical localization of glutamine synthetase in human liver.

Authors:  R Gebhardt; H Schmid; H Fitzke
Journal:  Experientia       Date:  1989-02-15

3.  Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.

Authors:  M H Werner; P A Humphrey; D D Bigner; S H Bigner
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

4.  Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.

Authors:  J A Biegel; D S Leslie; D D Bigner; S H Bigner
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Correlation of DNA ploidy and morphological features of human glioma cell cultures with the establishment of cell lines.

Authors:  K Onda; R Tanaka; K Washiyama; N Takeda; T Kumanishi
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Glial fibrillary acidic protein, vimentin and fibronectin in primary cultures of human glioma and fetal brain.

Authors:  A Paetau
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

7.  Characterization and chemosensitivity of two cell lines derived from human glioblastomas.

Authors:  I Izumu; K Mineura; K Watanabe; M Kowada
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

8.  Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas.

Authors:  Weidong Liu; Guohua Lv; Yawei Li; Lei Li; Bing Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.